Home > Boards > US OTC > Delisted > Cannabis Science Inc. (fka CBIS)

GW patent news. This is really good for

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
DouglasJH Member Profile
Followed By 0
Posts 872
Boards Moderated 0
Alias Born 08/28/09
160x600 placeholder
Kansas City Fed Services Activity Index Rises in January
By Colin Kellaher
Apple Up Over 5%, on Track for Largest Percent Increase Since October 2020 -- Data Talk
Intel on Track for Lowest Close Since December 2020 -- Data Talk
Visa Up Over 5%, on Pace for Largest Percent Increase Since November 2020 -- Data Talk
Oil Prices Seen at $78 This Year as Supply Hikes Lag Demand
US Consumer Sentiment Wanes in Late January to Decade-Low on Inflation Concerns
Insulet Shares Rally on FDA Approval of Omnipod 5
Provention Bio Shares Rise 13% After Plan to Resubmit BLA
Pfizer Gets EC OK for Lorviqua as First-Line Treatment for ALK-Positive Advanced Lung Cancer
Citi Works With Five Black-Owned Firms on Bond Issuance
Top Company News of the Day
U.S. Consumer Spending Fell 0.6% in December
Eli Lilly Reports Olumiant Setbacks in Lupus, Atopic Dermatitis
FTSE Down, Long Gilts Could Remain in Sweet Spot
Colgate-Palmolive Expects Earnings Growth This Year
Chevron Hits Production High in 2021, Net Output Down 5% in 4Q -- Energy Comment
Regeneron, Sanofi Pull FDA Application for Libtayo in Advanced Cervical Cancer
Bristol Myers Gets Positive CHMP Opinion For Breyanzi in Lymphoma
Colgate-Palmolive 4Q Profit Falls, Hit by Higher Costs
Merck: Molnupiravir Covid-19 Pill Effective Against Omicron in Lab Tests
EUROPEAN MIDDAY BRIEFING - Stocks Fall Ahead of Expected Mixed US Open
Insulet Gets FDA OK for Omnipod 5 Automated Insulin-Delivery System
North American Morning Briefing: S&P 500, Dow on Track for Fourth Weekly Loss
BOE Seen Trying to Encourage Stronger Pound, Says ING
Givaudan Shares Slide on Weak Profitability, Costs Impact
Belgian Economy Grew in 4Q at a Slower Pace
FTSE 100 Drops as Oil, Mining, Financial Stocks Fall
Henkel Shares Slide as 2022 Targets Fall Short of Consensus
DouglasJH   Thursday, 04/28/11 01:13:45 AM
Re: DouglasJH post# 23809
Post # of 129039 
GW patent news. This is really good for CBIS !!!

April has been a good month for UK drugmaker GW Pharmaceuticals - the company has now bagged an important US patent for its flagship product Sativex just weeks after hooking up Novartis as a marketing partner for the drug.

GW signs major Sativex MS deal with Novartis Study backs use of cannabis-based Sativex to treat MS GW rolls out cannabis-based MS drug Sativex in UK GW Pharma share boost on Sativex cancer pain data

The United States Patent and Trademark Office has granted the firm a patent protecting the use of Sativex (delta-9-tetrahydrocannabinol and cannabidiol) as a treatment for cancer pain, providing all-important exclusivity until April 2025.

The patent is related to a method of treating cancer-related pain with a combination of the two principal cannabinoids in Sativex, further strengthening the intellectual property protecting the product, providing GW with "a unique position to benefit from the rich promise within the field of cannabinoid therapeutics," noted the firm's chairman Geoffrey Guy.

The drug is currently approved in the UK, Spain, Czech Republic, Canada and New Zealand as a treatment for multiple sclerosis spasticity, but cancer pain represents the lead indication for Sativex in the US, where it is partnered with Otsuka Pharmaceutical.

The Japanese drugmaker is stumping up the cash for current Phase III clinical trials programme assessing the drug in this setting.

Novartis deal

Earlier this month, the company signed a deal with Novartis under which the latter will commercialise and assist in regulatory filings for Sativex in Australia and New Zealand, Asia (excluding Japan, China and Hong Kong), the Middle East (excluding Israel/Palestine) and Africa for the reduction of severe spasticity associated with multiple sclerosis.

The deal sees GW pocket a $5 million upfront fee and the Porton Down, England-based group will also be eligible for an extra $29 million on the achievement of certain approval and commercial milestones, as well as royalties.

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
Current Price
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences